|
| 35761129 | A pilot randomized controlled trial to evaluate a survivorship care planning intervention for head and neck cancer survivor-caregiver dyads. | J Cancer Surviv | 2024 |
| 36630663 | Increasing Racial and Ethnic Equity, Diversity, and Inclusion in Cancer Treatment Trials: Evaluation of an ASCO-Association of Community Cancer Centers Site Self-Assessment. | JCO Oncol Pract | 2023 |
| 37561967 | Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. | J Clin Oncol | 2023 |
| 37863501 | Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. | BMJ | 2023 |
| 37863491 | Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance. | BMJ | 2023 |
| 37489819 | The Targeted Agent and Profiling Utilization Registry Study: A pragmatic clinical trial. | Clin Trials | 2023 |
| 37643386 | Sponsor Perspectives on the Impact of the COVID-19 Pandemic on Interventional Cancer Clinical Trial Protocols and Data Quality. | JCO Oncol Pract | 2023 |
| 37315265 | Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With <i>ERBB2</i> Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study. | JCO Precis Oncol | 2023 |
| 37433103 | Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP. | J Clin Oncol | 2023 |
| 37027810 | Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With <i>ERBB2/3</i> Amplification, Overexpression, or Mutation: Results From the TAPUR Study. | JCO Precis Oncol | 2023 |
| 36753688 | Olaparib in Patients With Metastatic Prostate Cancer With <i>BRCA1</i>/<i>2</i> Mutation: Results From the TAPUR Study. | JCO Precis Oncol | 2023 |
| 36920457 | Rate of COVID-19 vaccination among patients with cancer who tested positive for severe acute respiratory syndrome-coronavirus 2: Analysis of the American Society of Clinical Oncology Registry. | Cancer | 2023 |
| 36529437 | Quasi-partial order continual reassessment method: Applying toxicity scores to cancer dose-finding drug combination trials. | Contemp Clin Trials | 2023 |
| 34655228 | Real-world Overall Survival Using Oncology Electronic Health Record Data: Friends of Cancer Research Pilot. | Clin Pharmacol Ther | 2022 |
| 35353546 | Pre-Treatment Staging Imaging in Rectal Cancer: Results From the Quality Oncology Practice Initiative. | JCO Oncol Pract | 2022 |
| 35442532 | Attention to diet, exercise, and weight in oncology care: Results of an American Society of Clinical Oncology national patient survey. | Cancer | 2022 |
| 35605183 | Sexual Orientation and Gender Identity Data Collection in Oncology Practice: Findings of an ASCO Survey. | JCO Oncol Pract | 2022 |
| 35467961 | Hematology/Oncology Fellowship Programs' Participation in the Quality Oncology Practice Initiative. | JCO Oncol Pract | 2022 |
| 35363501 | Relationship Between Participation in ASCO's Quality Oncology Practice Initiative Program and American Board of Internal Medicine's Maintenance of Certification Program. | JCO Oncol Pract | 2022 |
| 35588469 | Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement. | J Clin Oncol | 2022 |
| 35385345 | Optimal Sequential Predictive Probability Designs for Early-Phase Oncology Expansion Cohorts. | JCO Precis Oncol | 2022 |
| 36409971 | Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. | JCO Precis Oncol | 2022 |
| 36315917 | Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With <i>ERBB2</i> Amplification or <i>ERBB2/3</i> Mutations: Results From the TAPUR Study. | JCO Precis Oncol | 2022 |
| 36368340 | Demographic factors, psychiatric and physical comorbidities associated with starting preexposure prophylaxis in a nationally distributed cohort. | Prev Med | 2022 |
| 36240846 | Oral Chemotherapy Metric Performance in Quality Oncology Practice Initiative Practices: Updated Trends and Analysis. | J Natl Compr Canc Netw | 2022 |
| 36126244 | Oncologists' Perspectives on Individualizing Dose Selection for Patients With Metastatic Cancer. | JCO Oncol Pract | 2022 |
| 36394105 | Explicit underdose control based on toxicity: Four points to consider. | Stat Med | 2022 |
| 36186544 | Augmenting control arms with real-world data for cancer trials: Hybrid control arm methods and considerations. | Contemp Clin Trials Commun | 2022 |
| 34921524 | Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologists. | Cancer Med | 2022 |
| 35333502 | Clinical Evidence Generation During a Pandemic: Lessons Learned for Sustaining Progress. | Cancer J | 2022 |
| 34694907 | Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry. | JCO Oncol Pract | 2022 |
| 34664259 | The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies. | Clin Pharmacol Ther | 2022 |
| 33231866 | A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma. | Cancer | 2021 |
| 33622653 | Challenges and opportunities to developing a frailty index using electronic health record data. | J Geriatr Oncol | 2021 |
| 33844595 | Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. | J Clin Oncol | 2021 |
| 33563633 | Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group. | Clin Cancer Res | 2021 |
| 33563634 | Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-<i>Friends</i> Recommendations. | Clin Cancer Res | 2021 |
| 33705680 | Identification of Transgender People With Cancer in Electronic Health Records: Recommendations Based on CancerLinQ Observations. | JCO Oncol Pract | 2021 |
| 34755137 | Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. | Cell Rep Med | 2021 |
| 34312215 | A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop. | Clin Cancer Res | 2021 |
| 34003702 | Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. | J Clin Oncol | 2021 |
| 33309481 | Utilizing Data Visualization to Identify Survival and Treatment Differences Between Women With De Novo and Recurrent Metastatic Breast Cancer. | Clin Breast Cancer | 2021 |
| 32426702 | An assessment of racial differences in epidemiological, clinical and psychosocial factors among head and neck cancer patients at the time of surgery. | World J Otorhinolaryngol Head Neck Surg | 2020 |
| 35050752 | Palbociclib in Patients With Non-Small-Cell Lung Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. | JCO Precis Oncol | 2020 |
| 31815584 | Discrepancies in Financial Self-Disclosures and Open Payments Reporting Among Authors of Clinical Oncology Research Studies. | J Clin Oncol | 2020 |
| 32086341 | Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab. | Clin Cancer Res | 2020 |
| 31873943 | Geographically distributed data should be analyzed with spatial epidemiologic methods. | Cancer | 2020 |
| 33068284 | Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. | Target Oncol | 2020 |
| 33119031 | To Treat or Not to Treat-Balancing Benefits and Risks of Treatment Delay Among Patients With Cancer During the COVID-19 Pandemic. | JAMA Oncol | 2020 |
| 33090333 | Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. | Target Oncol | 2020 |